My HappyStock
Log in to track your learning progress.
US Companies
Find my preferred stocks →Compare companies across six criteria and explore businesses that fit your priorities.
NVO
Novo Nordisk A/S (NVO)
Average score 8.0 A
Preference —
Six company scores
Average score
Company growth8 / 10
Obesity drugs and diabetes demand fuel long-term sales
Profitability9 / 10
High-margin GLP-1 drugs and manufacturing scale
Financial stability7 / 10
Strong cash flows, but capex and borrowing increased
Economic moat9 / 10
Patents, clinical data and complex injectable capacity
Future outlook7 / 10
Oral GLP-1 upside faces competition and pricing pressure
Valuation8 / 10
About 12x forward earnings reflects slower growth risks
Editorial scores are for education, not audited financial metrics or investment advice.
Revenue by business
- Obesity Care 33.01%
Wegovy injections and tablets for weight management
- Diabetes Care 60.04%
Ozempic, Rybelsus, insulin and other diabetes drugs
- Rare Blood & Endocrine Disorders 6.95%
Haemophilia, growth hormone and rare endocrine therapies
Revenue by region
- United States 52.88%
- Europe and Canada 25.08%
- Emerging Markets 9.32%
- Asia-Pacific (ex-China) 6.36%
- China 6.36%
Key metrics
| Revenue CAGR (5 years) | 19% |
|---|---|
| Operating income CAGR (5 years) | 19% |
| Net income CAGR (5 years) | 19% |
| Operating margin (5-year avg.) | 43% |
| ROE (5-year avg.) | 75% |
| ROA (5-year avg.) | 21% |
| Beta (5 years) | 0.37 |
| MDD (5 years) | -75% |
| Payout ratio (5-year avg.) | 50% |
| P/E | 11x |
| Forward P/E | 12x |
| PEG | - |